Gilead Deal to Expand Access to Lenacapavir for PrEP Falls Short
October 8, 2024 — TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.

Statement on the UN High Level Meeting on Antimicrobial Resistance Final Draft Political Declaration
September 25, 2024 — Treatment Action Group (TAG) congratulates Malta and Barbados, co-facilitators, and all United Nations (UN) Member States participating in the High-Level Meeting on Antimicrobial Resistance (AMR) upon the publication of the final draft of the Political Declaration.

2024 Research in Action Awards Celebrate Leaders in Global Health Activism Who Exemplify TAG’s Mission
September 16, 2024 — Treatment Action Group’s (TAG) most important fundraising event of the year is the Research in Action Awards, which honor the best and brightest activists, researchers, leaders, and scientists whose work has been integral in ending HIV, tuberculosis (TB), and hepatitis C (HCV).

Treatment Action Group Calls for Coordinated, Fully Funded Global Response to Mpox Emergency
August 14, 2024 — Treatment Action Group (TAG) supports the World Health Organization (WHO) in declaring the renewed outbreak of mpox a public health emergency of international concern.

TAG Calls for Universal Access to Innovative HCV Testing to End the Disease by 2030
July 25, 2024 — This World Hepatitis Day, July 28, we are better positioned than ever to end hepatitis C Virus (HCV) as a pandemic.

Three New Members Elected to TAG’s Board of Directors
July 25, 2024 — Treatment Action Group (TAG) elected three new members to its Board of Directors in May 2024. Board President Ivy Kwan Arce said, “TAG is reinvigorating its Board in alignment with our vision, mission, and values.

TAG Calls on Danaher to Drop the Prices of GeneXpert Tests and Make the Cost Audit Public
June 26, 2024 — Treatment Action Group (TAG) calls on Danaher to lower the price of GeneXpert tests for tuberculosis (TB) and other diseases to $5 each in accordance with publicly available evidence of the cost of manufacturing and to commit to public transparency of the cost audit of Xpert MTB/RIF Ultra.

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions
June 20, 2024 — Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.

Treatment Action Group Calls on NY City Council to Override and Mayor Adams to Reverse Egregious Cuts to New York City HIV Funding
May 22, 2024 — In response to disheartening news of the proposed $5.3 million cut in HIV/AIDS funding by the Adams administration, we at Treatment Action Group (TAG) express our resolute opposition, in solidarity with our partner organizations that would be harmed by the egregious, unconscionable cuts to HIV services and programs in New…

Treatment Action Group Welcomes Two New Board Members
May 8, 2024 — Treatment Action Group (TAG) is pleased to announce that two new members have been elected to the Board of Directors, Ama Burnham and Dr. Stefan V. Goldberg.